Market Newsdesk

Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities

• Sanofi has successfully refinanced and extended two syndicated credit facilities for a total amount of €8 billion.
• Sanofi is the first large biopharmaceutical company to integrate environmental and social features in sustainability-linked credit facilities.

 

PARIS – December 9, 2020 – Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities.

These two facilities are part of Sanofi’s strategy to secure its long-term financing sources:

• A new €4 billion revolving credit facility expiring December 2025, with two extension options of one year each,
• An amendment of the €4 billion revolving credit facility expiring in December 2021 with the addition of two extension options of one year each.

Both revolving credit facilities (“RCFs”) incorporate an adjustment mechanism that links the cost of the facilities to the achievement of annual targets for two selected sustainable KPIs: contribution to Polio eradication and carbon footprint reduction.

Committed to fully embed sustainability in its business strategy (Play to Win), Sanofi decided to link part of its long-term financing to the fulfilment of two of Sanofi’s core commitments between now and 2025:

• Contribute to eradicate Polio, maintaining Sanofi’s key involvement in the very final step of the challenging journey towards eradication.
• Achieve a 30% reduction of its carbon footprint (scope 1 & 2) aligned with its validated SBTI goal (55% reduction by 2030 vs 2019), following the 1.5°C scenario. 

The innovative character of the transaction lies on Sanofi’s commitment to invest yearly a fixed contribution to both Sanofi’s Espoir Foundation and Sanofi Planet Mobilization program to fund social and environmentally responsible projects and maximize its impact on the two objectives. In case Sanofi achieves its yearly sustainability performance targets, Sanofi’s lending banks will support this contribution through a discount margin.

 “We took the opportunity of the refinancing of our €8 billion lines to link our facilities to our sustainability performance,” said Jean-Baptiste de Chatillon, Chief Financial Officer at Sanofi. “With this first sustainability-inked transaction, we are very proud to pioneer the sphere of Sustainable Finance for the pharmaceutical industry. Doing well and doing good at the same time is part of our DNA. We are convinced that this marks the first milestone of a long and promising journey to keep demonstrating the mobilization of all people at Sanofi towards sustainability”.

 “We are very pleased to begin our journey in Sustainable Finance with these two core facilities,” said Laurent Lhopitallier, Head of Corporate Social Responsibility Coordination and Reporting at Sanofi. “Being the first supplier of IPV¹ for GAVI² countries, Sanofi has historically played a critical role from the very beginning in the fight for Polio eradication which is considered as a top priority by the World Health Organization. Far from being reached, the final step is now critical, and Sanofi has made significant commitments to make this “end game” possible. As climate change is intimately linked to health, Sanofi as a healthcare company has an important role to play, therefore we are committed to act to reduce our Greenhouse gas emissions along our value chain”.

The refinancing was structured with BNP Paribas as syndication coordinator and Societe Generale and UniCredit Bank AG each as sustainability coordinator.

¹ Inactivated Poliovirus Vaccine

² GAVI is an international organization created in 2000 to improve access to new and underused vaccines for children living in the world’s poorest countries – https://www.gavi.org/

About Sanofi Espoir Foundation

Created in 2010, the Sanofi Espoir Corporate Foundation aims to reduce inequalities in health in France and internationally. Its actions aim to improve the health of the most vulnerable populations, particularly children. These serve the Foundation’s vision of a world in which everyone has a chance to be born, grow and maintain their health. This ambition covers four strategic areas: maternal and neonatal health, pediatric cancers in low- and middle-income countries, access to healthcare for the most vulnerable populations in France and responding to humanitarian crises.

About Sanofi Planet Mobilization

Sanofi’s environmental sustainability program, Planet Mobilization, assesses and limits the direct and indirect impacts of its products throughout their life cycle on human health and the environment. The company integrates issues on climate change into its culture by building them into decision-making processes and by measuring and limiting the impacts of its operations across its value chain. The World Health Organization expects climate change to cause an estimated 250,000 additional deaths each year
between 2030 and 2050.

About Sanofi   Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain end ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.   With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.   Sanofi, Empowering Life

Media Relations Contact Marion Breyer Tel.: +33 (0)1 53 77 46 46 [email protected]

Investor Relations Contact Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton   Investor Relations Contact North America Felix Lauscher Fara Berkowitz Suzanne Greco Tel.: +33 (0)1 53 77 45 45 [email protected] http://www.sanofi.com/en/investors/contact

Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the  ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing  could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare

 

 

Attachment

• Press release

This is a joint press release by Sanofi (“Sanofi“) and Kiadis Pharma N.V. (“Kiadis“), pursuant to the provisions of Section 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) and Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014), in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer“). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum (the “Offer Document“) approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) (the “AFM“) and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) (the ”FSMA”). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Sanofi and Kiadis satisfy competition condition related to the tender offer

Paris, France and Amsterdam, The Netherlands, 9 December 2020 – Sanofi (Euronext:


SAN and NYSE: SNY) and Kiadis Pharma N.V. (“Kiadis” or the “Company”)

(Euronext Amsterdam and Brussels: KDS)

Reference is made to the joint press release by Sanofi and Kiadis dated 2 November 2020 in respect of the Offer to be made by Sanofi at an offer price of EUR 5.45 in cash per share (cum dividend).

Sanofi and Kiadis confirm that they are making good progress on the preparations for the Offer. As announced on 30 November 2020, the Offer Document in relation to the Offer was filed with the AFM on 30 November 2020 and is under review.

Today, Sanofi and Kiadis jointly announce that the competition condition for completion of the Offer as announced in the press release of 2 November 2020, has now been satisfied.

Sanofi and Kiadis anticipate that the Offer will close in the first half of 2021.

Dutch Translation/Nederlandse vertaling

Parijs, Frankrijk en Amsterdam, Nederland, 9 december 2020 – Sanofi (Euronext:


SAN en NYSE: SNY) en Kiadis Pharma N.V. (“Kiadis” of de “Vennootschap”) (Euronext Amsterdam en Brussels: KDS)

Verwezen wordt naar het gezamenlijk persbericht van Sanofi en Kiadis van 2 november 2020 met betrekking tot het voorgenomen openbaar bod (het Bod) dat door Sanofi zal worden uitgebracht tegen een biedprijs van EUR 5,45 in contanten (cum dividend) per aandeel.

Sanofi en Kiadis bevestigen dat ze goede voortgang boeken met de voorbereidingen van het Bod. Zoals aangekondigd op 30 november 2020, is het biedingsbericht met betrekking tot het Bod op 30 november 2020 bij de Autoriteit Financiële Markten ingediend en wordt momenteel beoordeeld.

Sanofi en Kiadis maken vandaag bekend dat de mededingingsvoorwaarde voor gestanddoening van het Bod zoals aangekondigd in het persbericht van 2 november 2020, nu is vervuld.

Sanofi en Kiadis verwachten dat het Bod zal worden afgerond in de eerste helft van 2021.

Dit is een samenvatting van het Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.

For more information:

Kiadis: Maryann Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305 [email protected] Kiadis Media Relations Contacts LifeSpring Life Sciences Communication: Leon Melens (Amsterdam) Tel: +31 6 538 16 427 [email protected] Optimum Strategic Communications: Mary Clark, Supriya Mathur Tel: +44 203 950 9144 [email protected]

Sanofi : Sanofi Media Relations Contact Ashleigh Koss Tel.: +1 (908) 205-2572 [email protected] Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton Sanofi Investor Relations Contacts North America Felix Lauscher Fara Berkowitz Suzanne Greco IR main line: Tel.: +33 (0)1 53 77 45 45 [email protected]

About Kiadis

Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.Kiadis.com.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. Sanofi prevents illness with vaccines and provides innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Disclaimer

This is a joint public announcement by Kiadis and Sanofi pursuant to section 17 paragraph 1 and contains inside information within the meaning of section 7 paragraph 1 of the EU Market Abuse Regulation.

The information in the press release is not intended to be complete. This announcement is for information purposes only and does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities.

The distribution of this press release may, in some countries, be restricted by law or regulation. Accordingly, persons who come into possession of this document should inform themselves of and observe these restrictions. To the fullest extent permitted by applicable law, Sanofi and Kiadis disclaim any responsibility or liability for the violation of any such restrictions by any person. Any failure to comply with these restrictions may constitute a violation of the securities laws of that jurisdiction. Neither Sanofi, nor Kiadis, nor any of their advisors assumes any responsibility for any violation by any of these restrictions. Any Kiadis shareholder who is in any doubt as to his or her position should consult an appropriate professional advisor without delay.

Kiadis Forward-Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, risks related to Sanofi’s ability to complete the acquisition on the proposed terms or on the proposed timeline, the possibility that competing offers will be made, other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) — PubMatic, Inc. (Nasdaq: PUBM) today announced the pricing of its initial public offering of 5,900,000 shares of Class A common stock at a price to the public of $20.00 per share. PubMatic is offering 2,655,000 shares and certain selling stockholders are offering 3,245,000 shares. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to 885,000 additional shares of common stock at the initial public offering price, less underwriting discounts. PubMatic will not receive any proceeds from any sale of shares by the selling stockholders.

The shares are expected to begin trading on the Nasdaq Global Market on December 9, 2020 under the ticker symbol “PUBM.” The offering is expected to close on December 11, 2020, subject to customary closing conditions.

Jefferies LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC, KeyBanc Capital Markets, Oppenheimer & Co. Inc., and Raymond James & Associates, Inc. are acting as co-managers for the proposed offering.

The offering of these securities is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by email at [email protected]; or RBC Capital Markets, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089 or by email at [email protected].

A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission on December 8, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements
This press release contains forward looking statements, including statements regarding the proposed initial public offering. These statements are not historical facts but rather are based on PubMatic’s current expectations and projections regarding its business, operations and other factors relating thereto. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions are used to identify these forward looking statements. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those in PubMatic’s registration statement filed with the Securities and Exchange Commission.

Press Contact:

Ben Billingsley
Broadsheet Communications for PubMatic
[email protected]

Investors:

Dylan Solomon
The Blueshirt Group for PubMatic
[email protected] 

PADERBORN, Germany, and QUEBEC CITY, Canada, Dec. 09, 2020 (GLOBE NEWSWIRE) — dSPACE and LeddarTech®, a leader in level 1-5 ADAS and AD sensing technology, have entered into a partnership to jointly drive forward the development of lidar technologies for autonomous driving. The close cooperation will enable dSPACE and LeddarTech to provide high-precision simulation models and interfaces for lidar sensors, enabling OEMs and suppliers to integrate lidar innovations into ready-for-application solutions faster.

The cooperation will support the emulation of new LeddarTech laser sensors in simulation solutions at an early development stage. Moreover, dSPACE will provide simulation models for testing and validation, as well as the sensor simulation environment for validating camera, lidar and radar sensors throughout the development process – accelerating customers projects.

The dSPACE simulation solution generates point clouds in real time to simulate objects. The simulation models help determine the most effective positioning of the sensor on the vehicle (sweet spot), as well as the sensor limits (corner cases). LeddarTech will be able to seamlessly incorporate dSPACE’s sensor models into its development projects.

“The right testing strategy, the right models and ready-to-use interfaces for simulation and reprocessing are key building blocks,” said Dr. Christopher Wiegand, Product Manager at dSPACE. “This partnership will enable our customers to accurately and quickly perform validation tasks for lidar applications. Without reliable simulations, automated driving systems (SAE Levels 3-5) cannot be achieved.”

“OTA simulation is a key innovation for lidar. Integrating LeddarTech’s lidar products and dSpace’s simulation software through a generic sensor interface enables each party to validate products and services to potential customers,” stated Michael Poulin, Vice-President, Strategic Partnerships and Corporate Development at LeddarTech. He continued: “Enabling the validation of environmental sensors material properties and weather condition is crucial in simulations. LeddarTech and dSpace will work together on (further) developing and modelling sensor-specific environmental effects, e.g. rain, fog, spray, etc.”

About
dSPACE

dSPACE is a leading provider of solutions for developing connected, autonomous, and electrically powered vehicles. Particularly automotive manufacturers and their suppliers use the company’s end-to-end solution range to test the software and hardware components of their new vehicles long before a new model is allowed on the road. dSPACE is not only a sought-after development partner in vehicle development. Engineers also rely on our dSPACE know-how in aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With approximately 1,800 employees worldwide, dSPACE is headquartered in Paderborn, Germany; has three project centers in Germany; and serves customers through regional dSPACE companies in the USA, the UK, France, Japan, China, and Croatia.

About LeddarTech

LeddarTech is a leader in environmental sensing platforms for autonomous vehicles and advanced driver assistance systems. Founded in 2007, LeddarTech has evolved to become a comprehensive end-to-end environmental sensing company by enabling customers to solve critical sensing and perception challenges across the entire value chain of the automotive and mobility market segments. With its LeddarVision™ sensor-fusion and perception platform and its cost-effective, scalable, and versatile LiDAR development solution for automotive-grade solid-state LiDARs based on the LeddarEngine™, LeddarTech enables Tier 1-2 automotive system integrators, to develop full-stack sensing solution from level 1-5. This platform is actively deployed in autonomous shuttles, trucks, buses, delivery vehicles, smart cities/factories, and robotaxi applications. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 95 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook, and YouTube.

Contact:

Daniel Aitken, Vice-President, Global Marketing, Communications, and Product Management, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232
[email protected]

Contact:

dSPACE GmbH	dSPACE GmbH
Bernd Schäfers-Maiwald	Ulrich Nolte
Vice President Corporate Communication	Senior Communications Manager
Rathenaustraße 26	Rathenaustraße 26
33102 Paderborn	33102 Paderborn
Tel: +49 5251 1638-714	Tel.: +49 5251 1638-941
Fax: +49 5251 16198-714	Fax: +49 5251 16198-1448
E-mail: [email protected]	E-mail: [email protected], [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e95e1bf-b301-4b74-aea5-ea32de5a39ae

VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), is a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector. The Company is pleased to announce that it has signed a letter of intent (LOI) with The Nutraceutical Medicine Company Inc. (“PURICA”), owner of the PURICA™ brand of full-spectrum mushroom derived wellness products, to support Pure Extracts’ expansion into the functional mushroom sector and to co-develop CBD-full-spectrum mushroom wellness combinations.

PURICA has a track record of more than 20 years of bringing its customers the very best that nature has to offer; skillfully-formulated natural and whole food products solidly-backed by science. Based in Duncan, B.C. on Vancouver Island, PURICA is an award-winning company whose Immune 7 formulation has been named by Canadian retailers two years running as the gold award winner as the best immunity product in Canada in the prestigious alive Awards (2019 and 2020).

PURICA is also a leader in educating the public about the uses and benefits of medicinal full-spectrum mushrooms with formulations targeting immunity and stress relief, sleep, heart health, weight management, endurance, performance, hormonal balance and a host of other conditions.

Pure Extracts CEO, Ben Nikolaevsky, commented, “We are excited to be working with the experts at PURICA on functional mushroom products and novel CBD formulations. They have an impressive history of product development, customer retention and an unwavering dedication to high standards.”

The marriage of full-spectrum mushroom extracts and CBD would be a ground-breaking achievement and would uniquely position Pure Extracts at the confluence of two very powerful trends – the rapid adoption of CBD oil as a mainstream medicinal product and the explosive growth of functional mushroom wellness products. With the help of Pure Extracts’ scientific advisor, Dr. Alexander MacGregor, President of the Toronto Institute of Pharmaceutical Technology, the Company believes that it can expedite the formulation of this new category of wellness products with the highest bioavailability in the market today.

About Pure Extracts

(CSE: PULL)
(XFRA: A2QJAJ)

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

A


bout


P


URICA™


PURICA is a natural wellness and lifestyles company based in Duncan, B.C. It is the maker of highly-touted natural supplements such as PURICA Recovery and PURICA Recovery 3.0, immunity formulations such as the award-winning PURICA Immune 7 and PURICA Complete 360, PURICA Curcumin BioBDM30, other leading micronized medicinal mushroom and herbal formulations and more, including PURICA Probiotic, PURICA Power Vegan Protein and PURICA Zensations mushroom cacao mix. Our mission is to empower you to fully experience good health by providing the finest whole foods, supplements and lifestyle solutions. Our vision is a world in which you achieve your fullest potential in every aspect of life, work and play. PURICA = Nature. Science. You. For more visit www.purica.com.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD

“

Ben Nikolaevsky

”

Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

 

SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) — WatchGuard® Technologies, a global leader in network security and intelligence, advanced endpoint protection, multi-factor authentication and secure Wi-Fi, today announced the release of its Internet Security Report for Q3 2020. Top findings from the research reveal how COVID-19 has impacted the security threat landscape, with evidence that attackers continue to target corporate networks despite the shift to remote work, and a rise in pandemic-related malicious domains and phishing campaigns.

“As the impact of COVID-19 continues to unfold, our threat intelligence provides key insight into how attackers are adjusting their tactics,” said Corey Nachreiner, chief technology officer at WatchGuard. “While there’s no such thing as ‘the new normal’ when it comes to security, businesses can be sure that increasing protection for both the endpoint and the network will be a priority in 2021 and beyond. It will also be important to establish a layered approach to information security, with services that can mitigate evasive and encrypted attacks, sophisticated phishing campaigns and more.”

WatchGuard’s Internet Security Reports inform businesses, their partners and end customers with hard data, expert analysis and actionable insights on the latest malware and network attack trends as they emerge and influence the ever-evolving threat landscape. Key findings from the Q3 2020 report include:

• Network attacks and unique detections both hit two-year highs – Network attacks swelled to more than 3.3 million in Q3, representing a 90% increase over the previous quarter and the highest level in two years. Unique network attack signatures also continued on an upward trajectory, reaching a two-year high in Q3 as well. These findings highlight the fact that businesses must prioritize maintaining and strengthening protections for network-based assets and services, even as workforces become increasingly remote.
• COVID-19 scams grow in prevalence – In Q3, a COVID-19 adware campaign running on websites used for legitimate pandemic support purposes made WatchGuard’s list of the top 10 compromised websites. WatchGuard also uncovered a phishing attack that leverages Microsoft SharePoint to host a pseudo-login page impersonating the United Nations (UN), and the email hook contained messaging around small business relief from the UN due to COVID-19. These findings further emphasize that attackers will continue to leverage the fear, uncertainty, and doubt surrounding the global health crisis to entice and fool their victims.
• Businesses click on hundreds of phishing attacks and bad links – In Q3, WatchGuard’s DNSWatch service blocked a combined 2,764,736 malicious domain connections, which translates to 499 blocked connections per organization in total. Breaking it down further, each organization would have reached 262 malware domains, 71 compromised websites, and 52 phishing campaigns. Combined with the aforementioned rise in convincing COVID-19 scams, these findings illustrate the importance of deploying DNS filtering services and user security awareness training.
• Attackers probe for vulnerable SCADA systems in the U.S. – The one new addition to WatchGuard’s most-widespread network attacks list in Q3 exploits a previously-patched authentication bypass vulnerability in a popular supervisory control and data acquisition (SCADA) control system. While this class of vulnerability isn’t as serious as a remote code execution flaw, it could still allow an attacker to take control of the SCADA software running on the server. Attackers targeted nearly 50% of U.S. networks with this threat in Q3, highlighting that industrial control systems could be a major focus area for bad actors in the coming year.
• LokiBot look-a-like debuts as a top widespread malware variant – Farelt, a password stealer that resembles LokiBot, made its way into WatchGuard’s top five most-widespread malware detections list in Q3. Though it is unclear if the Farelt botnet uses the same command and control structure as LokiBot, there’s a high probability the same group, SilverTerrier, created both malware variants. This botnet takes many steps to bypass antivirus controls and fool users into installing the malware. While researching the threat, WatchGuard found strong evidence indicating the malware has likely targeted many more victims than the data suggests.
• Emotet persists – Emotet, a prolific banking trojan and known password stealer, made its debut on WatchGuard’s top ten malware list for the first time in Q3 and narrowly missed the top ten list of domains distributing malware (by only a few connections). Despite coming in at #11 for the latter list, this appearance is particularly notable, as the WatchGuard Threat Lab and other research teams have seen current Emotet infections dropping additional payloads like Trickbot and even the Ryuk ransomware with no signs of slowing down.

WatchGuard’s quarterly research reports are based on anonymized Firebox Feed data from active WatchGuard appliances whose owners have opted in to share data to support the Threat Lab’s research efforts. In Q3, nearly 48,000 WatchGuard appliances contributed data to the report (the most ever), blocking a total of more than 21.5 million malware variants (450 per device) and more than 3.3 million network threats (or roughly 70 detections per appliance). Firebox appliances continued their upward trend of unique signature detections as well, collectively identifying and blocking 438 unique attack signatures – a 6.8% increase over Q2 and the most since Q4 2018.

The complete report includes in-depth research and key defensive best practices that businesses of all sizes can use to protect themselves against modern security threats. The report also features a detailed analysis of the historic Twitter hack that compromised 130 high-profile accounts to promote a Bitcoin scam in July 2020.

Read WatchGuard’s full Q3 2020 Internet Security Report here today: https://www.watchguard.com/wgrd-resource-center/security-report-q3-2020.   

 

About WatchGuard Technologies, Inc.

WatchGuard® Technologies, Inc. is a global leader in network security, secure Wi-Fi, multi-factor authentication, advanced endpoint protection, and network intelligence. The company’s award-winning products and services are trusted around the world by nearly 18,000 security resellers and service providers to protect more than 250,000 customers. WatchGuard’s mission is to make enterprise-grade security accessible to companies of all types and sizes through simplicity, making WatchGuard an ideal solution for midmarket businesses and distributed enterprises. The company is headquartered in Seattle, Washington, with offices throughout North America, Europe, Asia Pacific, and Latin America. To learn more, visit WatchGuard.com.

For additional information, promotions and updates, follow WatchGuard on Twitter @WatchGuard on Facebook or on the LinkedIn Company page. Also, visit our InfoSec blog, Secplicity, for real-time information about the latest threats and how to cope with them at www.secplicity.org. Subscribe to The 443 – Security Simplified podcast at Secplicity.org, or wherever you find your favorite podcasts.

WatchGuard is a registered trademark of WatchGuard Technologies, Inc. All other marks are property of their respective owners.

###

Chris Warfield
WatchGuard Technologies, Inc 
206.876.8380
[email protected]

Anthony Cogswell
Voxus PR
253.444.5980
[email protected]

LUBBOCK, Texas, Dec. 09, 2020 (GLOBE NEWSWIRE) — Solomon E. Fields offers a concise resource tool for those who minister through preaching, teaching and leading Bible studies around the signs within the gospel of John in his new book “The Signs of Jesus’ Deity in the Gospel of John” (published by Archway Publishing).

 

There are several towns in which Jesus performed miracle signs: Jerusalem, Cana and Bethany. Some miracles took place on the Sea of Galilee also known as the Sea of Tiberias and the mountain side of the regions of Galilee and Judea. But there is the question of whether each miracle sign, individually proves the deity of Jesus Christ or if John means the collective group of miracles prove the deity. The purpose of the book is to address the miracle signs in the Gospel of John and the impact of these upon the immediate audience and the future readers of the Gospel.

 

“I believe people are looking for help and hope during these times. Some are even questioning whether there is a God,” Fields says. “This writing gives hope and help in the person of Jesus Christ, regardless of the trouble, trauma or tragedy that a person is facing. Jesus has the power to deal with any and all situations in our lives.”

 

“The Signs of Jesus’ Deity in the Gospel of John” is available for purchase from the Archway link above, Barnes & Noble and Amazon at: https://www.amazon.com/Signs-Jesus-Deity-Gospel-John/dp/1480891800.

 

“The Signs of Jesus’ Deity in the Gospel of John”

By Solomon E. Fields

Hardcover | 5.5 x 8.5 in | 236 pages | ISBN 9781480891821

Softcover | 5.5 x 8.5 in | 236 pages | ISBN 9781480891807

E-Book | 236 pages | ISBN 9781480891814

Available at Amazon and Barnes & Noble

 

About the Author

Solomon E. Fields is a preacher and teacher who has conducted numerous revivals and workshops within Texas. He has over 29 years of ministry experience that includes 26 years of pastoring at St. John Baptist Church in Lubbock, Texas. Fields holds a Bachelor of Arts in communications, a Master of Arts and doctorate in biblical studies and a certificate of chaplaincy. He and his wife reside in Lubbock, Texas.

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 844-669-3957.

Attachment

• Cover_l

Marketing Services
Archway Publishing
844-669-3957
[email protected]

HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE) — Randall L. Hull explains his steps on how to keep working to “form a more perfect union” and fight political hypocrisy with the insights and ideas in “Political Malpractice in America: Republic at Risk” (published by Archway Publishing).

 

The author explains how the United States is the richest in the world yet the distribution of economic gains increasingly goes to a smaller and smaller segment of society. Hull describes how the nation has created, in effect, a new aristocracy with little or no control over how this group “buys” a government that works for them at the expense of the common good. The author then goes on to not only convey how the United States got into their current situation by analyzing political and economic decisions of the past 40 years in America, but also how the country might begin to work their way out of it.

 

“Our country is more divided then at any time since the Civil War and our political leaders are failing to confront these challenges.  Our 244-year-old Republic is in peril,” Hull says. “Hopefully readers will take on a sense of urgency to demand that their political and business leaders collaborate to solve the challenges that increasingly threaten the future of our democracy.”

 

“Political Malpractice in America” is available for purchase online at: https://www.archwaypublishing.com/en/bookstore/bookdetails/803625-political-malpractice-in-america.

 

“Political Malpractice in America”

By Randall L. Hull

Hardcover | 6 x 9 in | 220 pages | ISBN 9781480891715

Softcover | 6 x 9 in | 220 pages | ISBN 9781480891722

E-Book | 220 pages | ISBN 9781480891739

Available at Amazon and Barnes & Noble

 

About the Author

Randy Hull is a retired global business executive who worked in the energy and chemicals industries for over 40 years. He is an honors graduate in mechanical engineering from Lehigh University (1973) and also holds a Master of Business Administration from Harvard University (1978). He is a member of the American Institute of Chemical Engineers and a member of both Tau Beta Pi and Pi Tau Sigma engineering honorary societies. He is married to Patricia Perrin Hull and is the father of two daughters. He has enjoyed a lifelong love affair with U.S. history and lives in Houston, Texas.

Simon & Schuster, a company with nearly ninety years of publishing experience, has teamed up with Author Solutions, LLC, the worldwide leader in self-publishing, to create Archway Publishing. With unique resources to support books of all kind, Archway Publishing offers a specialized approach to help every author reach his or her desired audience. For more information, visit www.archwaypublishing.com or call 844-669-3957.

Attachment

• Cover_l

Marketing Services
Archway Publishing
844-669-3957
[email protected]